ArticleBMC infectious diseases2026
Transmission and cost-effectiveness modelling to estimate the progress towards elimination and future strategy optimisation for gambiense human African trypanosomiasis in Uganda.
Article in BMC infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
19 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGambiense human African trypanosomiasis (gHAT) is a vector-borne disease with hundreds of thousands of people living at risk across Sub-Saharan Africa. Uganda, having reduced gHAT cases reported annually from 948 in 2000 to zero local cases since 2020, is a frontrunner to be verified by the World Health Organization (WHO) as having achieved elimination of transmission (EoT) of gHAT. It is now crucial to quantify the impact of the interventions deployed, quantify whether the last transmission event (LTE) and last case have already occurred, and determine the resources required to sustain the gains.
methodsWe employed a suite of mechanistic compartmental gHAT models, fitted to data from seven districts (Adjumani, Amuru, Arua, Koboko, Maracha, Moyo, and Yumbe) in Uganda that reported gHAT cases during 2000-2022, to address these questions. By combining and weighting the evidence from each model variant, we captured the uncertainty of achieving different elimination metrics across Uganda. Additionally, we utilised the dynamic transmission model outputs to perform a health economic analysis, identifying the most cost-effective strategies to avert disease burden.
resultsPredictions estimate that Uganda had the LTE in or before 2021 with high certainty (>95%). The model suggests that the local Ugandan case reported in 2019 may have been the last, but that there remains a 1.13% chance that cases could be reported after 2025. The cost-effectiveness analysis recommends that as transmission dynamics remain similarly low across all strategies, the Stop 2026 strategy, in which there is only passive screening from 2026 and subsequent reactive screening and vector control are only implemented if cases are detected, has the highest probability of being cost-effective and is predicted to have an economic cost of $193K ($161K-$220K) between 2026 and 2040.
conclusionsTo sustain Uganda's success whilst ensuring efficient resource use, this modelling analysis recommends implementing the Stop 2026 strategy in all seven analysed districts, which focuses on maintaining strong passive screening post-2026. This recommendation aligns with the current gHAT strategy in Uganda.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.